underwriters expect to deliver the shares on or about                  , 2018.Joint Book-Running ManagersBarclaysUBS Investment BankBMO Capital MarketsLead ManagerCanaccord GenuityProspectus dated                  , 2018TABLE OF CONTENTSPagePROSPECTUS SUMMARY1RISK FACTORS13INFORMATION REGARDING FORWARD-LOOKING STATEMENTS57INDUSTRY AND MARKET DATA59USE OF PROCEEDS60DIVIDEND POLICY62CAPITALIZATION63DILUTION64SELECTED FINANCIAL DATA66MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND PLAN OF OPERATIONS68BUSINESS83MANAGEMENT137EXECUTIVE AND DIRECTOR COMPENSATION145CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS156PRINCIPAL SHAREHOLDERS160DESCRIPTION OF CAPITAL STOCK161SHARES ELIGIBLE FOR FUTURE SALE164MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS OF OUR COMMON
not adequately protect our product candidates, others could compete against us more directly, which would harm our business, possibly materially.•An active trading market for our common stock may not develop, and you may not be able to sell your common stock at or above the initial public
elect to avail ourselves of the controlled company exemption under the corporate governance requirements of the Nasdaq.Directed share programAt our request, the underwriters have reserved up to 5% of the common stock being offered by this prospectus for sale at the initial public offering price to our directors, officers, employees and
candidates that we may pursue;•continue to build our portfolio of product candidates through the acquisition or in-license of additional product candidates or technologies;•continue to develop, maintain, expand and protect our intellectual property portfolio;•pursue regulatory approvals for our current and future product candidates that successfully complete clinical trials;13Table of Contents•ultimately establish a sales, marketing and distribution infrastructure to commercialize any product candidate for which we may obtain
range of challenging activities, including completing clinical trials of our product candidates, developing commercial scale manufacturing processes, obtaining marketing approval, manufacturing,
if we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.We anticipate that our expenses will increase substantially if and as we continue to develop and begin clinical trials with respect to BXCL501,
may obtain marketing approval, if any; require the manufacture of larger quantities of product candidates for clinical development and, potentially, commercialization; maintain, expand and protect our
Our future funding requirements, both short-term and long-term, will depend on many factors, including:•the scope, progress, timing, costs and results of clinical trials of BXCL501, BXCL701 and our other product candidates;•our ability to enter into and the terms and timing of any collaborations, licensing agreements or other arrangements;•the costs, timing and outcome of seeking regulatory approvals;•the costs of commercialization activities for any of our product candidates that receive marketing approval to the extent such costs are not
infrastructure;•revenue received from commercial sales, if any, of our current and future product candidates;•the costs of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property rights and defending
against intellectual property related claims;•the number of future product candidates that we pursue and their development requirements;•changes in regulatory policies or laws that may affect our operations;•changes in physician acceptance or medical society recommendations that may affect commercial efforts;•the costs of acquiring potential new product candidates or technology; and•the costs of operating as a public company.15Table of ContentsRisks Related to the Discovery and Development of Product CandidatesWe have limited experience in drug discovery and drug development, and we have never
unable to initiate or complete the clinical development of, obtain marketing approval for or successfully commercialize BXCL501, BXCL701 and our other product candidates, either alone or with a
collaborator, or if we experience significant delays in doing so, our business could be substantially harmed.We currently do not have any products that have received regulatory approval and may never be able to develop marketable product candidates.
ability, or that of any future collaborator, to develop, obtain marketing approval for and successfully commercialize product candidates in one or more disease indications.The
marketing approval;•the performance of our future collaborators, if any;•the extent of any required post-marketing approval commitments to applicable regulatory authorities;•establishment of supply arrangements with third-party raw materials suppliers and manufacturers;•establishment of arrangements with third-party manufacturers to obtain finished drug product that is appropriately packaged for sale;•adequate ongoing availability of raw materials and drug product for clinical development and any commercial sales;•obtaining and maintaining patent, trade secret protection and regulatory exclusivity, both in the United States and internationally;•protection of our rights in our intellectual property portfolio;•successful launch of commercial sales following any marketing approval;16Table of Contents•a continued acceptable safety profile following any marketing approval;•commercial acceptance by patients, the medical community and third-party payors; and•our ability to compete with other therapies.Many
lengthy, time consuming, expensive and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.The time required to obtain approval by the FDA and comparable foreign authorities is unpredictable but typically takes many years following the
manage the execution and completion of any clinical trials we initiate in a way that leads to our obtaining marketing approval for our product candidates in a timely manner, or at all.
our products do not gain market acceptance, we may not be able to fund future operations, including developing, testing and obtaining regulatory approval for new product candidates
Third-party collaborators may assist us in:•funding research, preclinical development, clinical trials and manufacturing;39Table of Contents•seeking and obtaining regulatory approvals; and•successfully commercializing any future product candidates.If
product candidate that we acquire may require additional development efforts prior to commercial sale, including extensive clinical testing and approval by the FDA and applicable foreign